Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 13 of 40 · 1918 articles
Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Research and clinical trials.
Biopsy-based keratin patterns might help distinguish IBD, microscopic colitis, and IBS—conditions that can look similar clinically—so this could improve diagnostic accuracy if validated.
PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be...
People with UC often use probiotics or microbiome-directed therapies alongside prescription drugs. Understanding probiotic–drug interactions could explain why individuals respond differently to IBD treatments and may...
Surgery is still a core part of care for certain UC and Crohn's patients despite better medical therapies. Newer surgical techniques and coordinated medical–surgical approaches aim to reduce complications and recurrence...
Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...
Many people with UC try dietary supplements; this randomized trial tested grape seed extract and found a measurable reduction in an inflammation blood marker (hs‑CRP) but no clear improvement in most other measured...
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new...
People with ulcerative colitis may be interested because the study explores a plant extract that reduced inflammation markers in a common animal model of colitis, suggesting a possible new avenue for drug discovery or...
A decreasing need for IBD-related surgery after pediatric diagnosis could mean fewer major operations and related recovery for children and young adults. It may reflect the growing use of advanced medical therapies in...
A common heart drug, verapamil, reduced disease signs in a mouse model of colitis and altered inflammation and the gut microbiota — suggesting a possible avenue for future IBD research. These are preclinical results, so...
This study identifies reproducible molecular patterns in UC tissue that could help researchers target non-immune pathways (metabolic/mitochondrial) in addition to inflammation, and it highlights that apparently...
Illness perceptions and perceived ability to understand health information are linked to self-care in IBD. If worse illness perceptions tend to lead to later increases in perceived difficulty understanding written...
Cure8 could only read part of this source from newschannel9.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
The review connects Western diet-driven metabolic shifts in the gut, immune cells, and microbiota to ulcerative colitis mechanisms and highlights metabolism-targeting therapies as a potential future avenue for treatment.
This trial represents an early-stage clinical test of a new investigational drug (ATTO-1091) for people with ulcerative colitis; Phase 1 studies establish initial safety and how the drug behaves in the body, which are...
The study aims to map the specific peptide targets of T cells driving organ inflammation in autoimmune diseases, which could guide development of antigen-specific, tolerogenic treatments relevant to Crohn's disease and...
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Anti-TNF. The original article is from iScience.
The paper identifies a molecular pathway (SERPINB5–MMP9–RLN2) by which the HDAC inhibitor trichostatin A reduced inflammation and protected the intestinal barrier in mouse and cell models of ulcerative colitis,...
Extraintestinal manifestations (skin, joint, eye, liver) are common in IBD and can greatly affect quality of life; better recognition and coordinated care can speed diagnosis and improve outcomes.
The paper identifies a molecular pathway (miR-31-5p/SATB2) linked to UC progression to colitis-associated cancer and reports that resveratrol modulates this axis in mice, suggesting a potential preventive mechanism worth...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. The original article is from Scandinavian Journal of...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Urgency. The original article is from Gastro hep advances.
If confirmed, a pathology marker visible on routine biopsy (EGC patterns by SOX10 IHC) could help predict which children with ulcerative colitis are more likely to have improved mucosal inflammation over the first year,...
Based on the title and source metadata, this appears to be a regulatory update related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunopharmacology...
If EPS helps restrain inflammation by shifting macrophages toward an M2 phenotype and is reduced in active UC, it could help explain mechanisms of mucosal inflammation and point to new biomarker or therapeutic strategies...
CMV colitis can complicate moderate–severe UC flares and—if present—is associated here with longer hospital stays, more frequent escalation to anti‑TNF therapy, and higher colectomy risk.
The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...
Disease-related changes in liver drug-metabolizing enzymes may alter how herbal formulas or medications are processed in people with UC, potentially affecting efficacy or safety. Understanding the mechanisms helps inform...
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
Fungi in the gut appear to influence immune pathways implicated in IBD and other autoimmune diseases, suggesting new therapeutic targets and microbiome-based interventions that could affect disease activity.
Shifting to patient-initiated, digitally supported follow-up could maintain disease control while reducing routine fixed-interval visits and improving patient experience — relevant as IBD patient numbers grow and clinic...
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
If validated, impaired oxalate handling could help explain why some people with IBD react differently to the same plant-rich diet and point to new dietary or microbiome-based interventions to reduce gut inflammation.
Researchers and clinicians are watching new oral therapies for patients whose disease has failed biologic treatments. If supported by full data, a safe, oral drug that helps refractory Crohn’s disease and ulcerative...
This hire signals Coultreon is prioritizing commercial and development work on its SIK3 inhibitor COL-5671, which the company highlights as a potential oral treatment relevant to ulcerative colitis and Crohn’s disease.
People with UC on tofacitinib may experience asymptomatic reactivation of HSV or VZV detectable by PCR, which could be relevant for infection monitoring and vaccination discussions. The study did not find clear links to...
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
Fatigue is a common, disabling symptom in people with quiescent IBD and currently lacks approved pharmacological treatments. This trial tests whether modafinil can safely reduce fatigue and improve daily functioning for...
Psychological distress and gut–brain interactions can worsen quality of life and IBD outcomes. A culturally tailored, scalable digital mind–body program could improve access to psychosocial care for Black and Hispanic...
Reports a rare co-occurrence of SMAS and nutcracker phenomenon in a person with active ulcerative colitis; highlights that weight loss and obstructive symptoms in IBD may have uncommon anatomical causes.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Materials today. Bio.
Pathology reports often list microscopic findings that reflect disease activity. Knowing which histologic features are frequently seen in relapsing ulcerative colitis helps patients and clinicians interpret biopsy...
PUC often behaves differently and more aggressively than adult-onset UC; understanding pediatric‑specific causes and treatments could lead to better, more effective therapies for children.
A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other...
